A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

@article{Raskin2000A1C,
  title={A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.},
  author={Philip R Raskin and Leslie J. Klaff and Richard M. Bergenstal and Jean Halle and David S. Donley and Tatiana Pontrelli Mecca},
  journal={Diabetes care},
  year={2000},
  volume={23 11},
  pages={1666-71}
}
OBJECTIVE To determine the safety and efficacy of the long-acting insulin analog, insulin glargine, as a component of basal bolus therapy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS Patients with type 1 diabetes receiving basal-bolus insulin treatment with NPH human insulin and insulin lispro were randomized to receive insulin glargine (HOE 901), a long-acting basal insulin analog, once a day (n = 310) or NPH human insulin (n = 309) as basal treatment with continued bolus… CONTINUE READING